RECRUITING

Atlantic Lipid Lowering Treatment Optimization Program

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. To help address this in our community, Atlantic Medical Group (AMG) formed a lipid workgroup chaired by Robert D. Fishberg, MD, and Jeffrey N. Feldman, MD. The overarching goal of the lipid workgroup is to enhance the treatment of lipid disorders in those patients with abnormal lipid levels by improving access to resources at the primary care practice level and specialty level. We aim to develop a model for primary and secondary prevention that integrates guidelines for treatment at the practice level. Our primary objective is to identify high-risk patients by utilizing the electronic health record and partnering with patients' primary care providers to provide comprehensive medical management.

Official Title

Atlantic Lipid Lowering Treatment Optimization Program (ALLTOP): A Comprehensive Approach to the Treatment of Familial Hypercholesterolemia and Complex Dyslipidemias

Quick Facts

Study Start:2024-07-01
Study Completion:2027-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06439654

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 120 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * LDL-C ≥160 mg/dL
  2. * Untreated LDL-C ≥190 with family history of CAD
  3. * Prior MI and currently without optimized lipid-lowering therapy
  4. * Family history of CAD in first degree relative
  5. * Personal history of CAD
  6. * Untreated triglycerides \>500
  7. * Elevated Lp(a) and/or high calcium scores
  8. * Consenting individuals
  1. * Individuals who are pregnant
  2. * Individuals who are incarcerated
  3. * Individuals with a terminal illness
  4. * Individuals who do not consent

Contacts and Locations

Study Contact

Robert D Fishberg, MD
CONTACT
973-467-0005
robert.fishberg@atlantichealth.org
Jeffrey N Feldman, MD
CONTACT
908-686-9330
jeffrey.feldman@atlantichealth.org

Principal Investigator

Robert D Fishberg, MD
PRINCIPAL_INVESTIGATOR
Atlantic Health System

Study Locations (Sites)

Atlantic Medical Group
Clark, New Jersey, 07066
United States
Atlantic Medical Group
Springfield, New Jersey, 07081
United States

Collaborators and Investigators

Sponsor: Atlantic Health System

  • Robert D Fishberg, MD, PRINCIPAL_INVESTIGATOR, Atlantic Health System

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-01
Study Completion Date2027-12-31

Study Record Updates

Study Start Date2024-07-01
Study Completion Date2027-12-31

Terms related to this study

Keywords Provided by Researchers

  • LDL-C
  • FH
  • complex dyslipidemia

Additional Relevant MeSH Terms

  • Familial Hypercholesterolemia
  • Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia
  • Apolipoprotein B 100, Familial Defective
  • High Density Lipoprotein Deficiency
  • Low-Density-Lipoid-Type Hyperlipoproteinemia